These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19939700)

  • 1. Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status.
    Ngeow J; Leong SS; Gao F; Toh CK; Lim WT; Tan EH; Poon D
    Crit Rev Oncol Hematol; 2010 Oct; 76(1):53-60. PubMed ID: 19939700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly.
    Leong SS; Toh CK; Lim WT; Lin X; Tan SB; Poon D; Tay MH; Foo KF; Ho J; Tan EH
    J Thorac Oncol; 2007 Mar; 2(3):230-6. PubMed ID: 17410046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
    Liu S; Wang D; Chen B; Wang Y; Zhao W; Wu J
    Lung Cancer; 2011 Aug; 73(2):203-10. PubMed ID: 21211862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC.
    Gridelli C; Hainsworth J
    Lung Cancer; 2002 Dec; 38 Suppl 4():37-41. PubMed ID: 12480193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).
    Des Guetz G; Landre T; Westeel V; Milleron B; Vaylet F; Urban T; Barlesi F; Souquet PJ; Debieuvre D; Braun D; Fraboulet G; Monnet I; Uzzan B; Molinier O; Morin F; Moro-Sibilot D; Morère JF
    J Geriatr Oncol; 2015 May; 6(3):233-40. PubMed ID: 25698450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities--a multicenter phase II trial.
    Hirsh V; Latreille J; Kreisman H; Desjardins P; Ofiara L; Whittom R; Fox S; Palayew MD; Pintos J
    Lung Cancer; 2005 Jul; 49(1):117-23. PubMed ID: 15949597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.
    Gridelli C; Perrone F; Gallo C; Cigolari S; Rossi A; Piantedosi F; Barbera S; Ferraù F; Piazza E; Rosetti F; Clerici M; Bertetto O; Robbiati SF; Frontini L; Sacco C; Castiglione F; Favaretto A; Novello S; Migliorino MR; Gasparini G; Galetta D; Iaffaioli RV; Gebbia V;
    J Natl Cancer Inst; 2003 Mar; 95(5):362-72. PubMed ID: 12618501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
    Dong X; Hao Y; Wei Y; Yin Q; Du J; Zhao X
    PLoS One; 2014; 9(3):e92320. PubMed ID: 24647522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.
    Curran MP; Plosker GL
    Drugs Aging; 2002; 19(9):695-721. PubMed ID: 12381238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients.
    Comella P; Frasci G; Carnicelli P; Massidda B; Buzzi F; Filippelli G; Maiorino L; Guida M; Panza N; Mancarella S; Cioffi R
    Br J Cancer; 2004 Aug; 91(3):489-97. PubMed ID: 15266334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
    Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
    Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
    Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study.
    Karampeazis A; Vamvakas L; Agelidou A; Kentepozidis N; Chainis K; Chandrinos V; Vardakis N; Pallis AG; Christophyllakis C; Georgoulias V
    Clin Lung Cancer; 2011 May; 12(3):155-60. PubMed ID: 21663857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience.
    Pallis AG; Polyzos A; Boukovinas I; Agelidou A; Lamvakas L; Tsiafaki X; Agelidou M; Pavlakou G; Chandrinos V; Kakolyris S; Christophyllakis C; Kentepozidis N; Giassas S; Androulakis N; Agelaki S; Georgoulias V
    J Thorac Oncol; 2008 May; 3(5):505-10. PubMed ID: 18449003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
    Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment.
    Meert AP; Berghmans T; Branle F; Lemaître F; Mascaux C; Rubesova E; Vermylen P; Paesmans M; Sculier JP
    Anticancer Res; 1999; 19(5C):4379-90. PubMed ID: 10650780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
    Pujol JL; Breton JL; Gervais R; Rebattu P; Depierre A; Morère JF; Milleron B; Debieuvre D; Castéra D; Souquet PJ; Moro-Sibilot D; Lemarié E; Kessler R; Janicot H; Braun D; Spaeth D; Quantin X; Clary C
    Ann Oncol; 2005 Apr; 16(4):602-10. PubMed ID: 15741225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
    Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
    Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.